Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 3, 2001, Pages 251-254

  Gil Delgado, M A ^a   Antoine, E C ^a   Guinet, F ^b   Bassot, V ^a   Grapin, J P ^a   Benhammonda, A ^a   Adam, R ^a   Castaing, D ^b   Bismuth, H ^b   Khayat, D ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

Gastrointestinal cancer; Irinotecan; Mitomycin C

Indexed keywords

IRINOTECAN; MITOMYCIN C;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DOSE CALCULATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM STAGING;

EID: 0034984358     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200106000-00008     Document Type: Article

References (16)

1. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer
2. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pre-treated with fluorouracil-based chemotherapy
3. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
4. Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer
5. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5 fluorouracil (5FU)
6. CPT- 11 (irinotecan) and 5 fluorouracil: A promising combination for therapy of colorectal cancer
7. Phase I study of a weekly infusion of irinotecan, high-dose leucovorin and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer
8. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dosefinding and pharmacokinetic study in patients with pre-treated metastatic colorectal cancer
9. Mitomycin C: A review
10. Reporting results of cancer treatment
11. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer
12. Phase III study of chronomodulated vs protracted venous infusional 5 fluorouracil both combined with mitomycin in first line therapy for advanced colorectal carcinoma
13. Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis
14. Renal disease after mitomycin C therapy
15. Characterisation and clinical management of CPT- 11 (irinotecan)-induced adverse events: The European prospective
16. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil